Table 4. Sleep problems and quality of life at week -12 in the two groups.
| Gabapentin | Placebo | p-Value | |
|---|---|---|---|
| Mean (SD) | Mean (SD) | ||
| MOS-Sleep | |||
| Sleep disturbance | 32.7±21.7 | 22.8±26.6 | 0.028 |
| Snoring | 49.7±33.4 | 46.2±41.3 | 0.759 |
| Awakens short of breath or headache | 16.1±25.5 | 5.0±12.6 | 0.032 |
| Sleep adequacy | 70.3±26.2 | 78.7±26.2 | 0.005 |
| Day-time somnolence | 35.9±22.5 | 24.2±20.1 | 0.126 |
| Sleep problems Index | 25.4±19.8 | 17.4±15.6 | 0.038 |
| MOS-Sleep: optimal sleep | n/N (%) | n/N (%) | 0.392 |
| 19/33 (57.6) | 20/42 (47.6) | ||
| SF-12 | |||
| Physical functioning | 44.9±11.8 | 51.5±7.5 | 0.005 |
| Role Physical | 26.1±4.1 | 28.7±2.3 | 0.001 |
| Role emotional | 18.7±5.2 | 21.8±2.6 | 0.001 |
| Mental Health | 45.3±10.2 | 53.7±8.1 | <0.001 |
| Bodily pain | 47.6±12.5 | 53.1±7.9 | 0.026 |
| General Health | 43.4±10.8 | 45.8±9.4 | 0.315 |
| Vitality | 50.9±10.7 | 54.8±9.4 | 0.105 |
| Social Functioning | 47.8±11.1 | 49.5±11.2 | 0.508 |
| Summary Scale Physical | 44.1±9.9 | 47.8±6.6 | 0.061 |
| Summary Scale Mental | 38.1±9.0 | 42.6±6.5 | 0.018 |
Abbreviations: SD: standard deviation; SF-12: Short-Form 12; MOS-Sleep: Medical Outcomes Study.